Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen

NCT01042925 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01042925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01042925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2010
Completion date
December 31, 2012
Enrollment
42 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms